This program is designed for respiratory care professionals seeking advanced knowledge in the management of COPD and Alpha-1 Antitrypsin (AAT) Deficiency. Participants will gain a comprehensive understanding of AAT deficiency, including identification, genetic testing, and allele interpretation to determine eligibility for augmentation therapy.
The course will cover the principles and administration of augmentation therapy, the critical role of Registered Respiratory Therapists (RRTs) in patient care, and strategies for promoting awareness, education, and smoking cessation in clinical, community, and home settings. By completing this program, learners will be equipped to apply their expertise to improve patient outcomes and advance professional practice.
- Describe the pulmonary manifestations of Alpha-1 Antitrypsin Deficiency and the relevance of A1AD knowledge to respiratory therapy practice.
- Explain the importance of including Alpha-1 Antitrypsin Deficiency in the respiratory therapist’s clinical assessment of patients with obstructive lung disease.
- Identify clinical indicators and situations in which respiratory therapists should consider Alpha-1 Antitrypsin Deficiency in acute and chronic care settings.
- Differentiate the responsibilities of respiratory therapists related to Alpha-1 Antitrypsin Deficiency across inpatient, outpatient, and home care settings.
- Discuss strategies respiratory therapists can use to increase awareness of Alpha-1 Antitrypsin Deficiency among patients, families, healthcare providers, and the community.